The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The p38 mitogen-activated protein kinase (MAPK) is activated by various pro-inflammatory and stressful stimuli. Mounting evidence suggests that the p38 MAPK signaling cascade is involved in various biological responses other than inflammation such as cell proliferation, differentiation, apoptosis and invasion, suggesting that the p38 MAPK can serve as a potential therapeutic target for the treatment of not only inflammatory diseases but also cancer. METHODS: The unique characteristics of p38 MAPK are summarized with regard to activation and function of p38 MAPK signaling cascades. We then discuss the involvement of p38 MAPK in diseases and the implications of the possible therapeutic use of p38 MAPK inhibitors. The p38 MAPK inhibitors that have been used in the in vitro/in vivo systems as well as in the clinical trials are summarized. RESULTS/CONCLUSION: The p38 MAPK plays an important role in key cellular processes related to inflammation and cancer. Understanding the signal transduction mechanisms and gene regulation by p38 MAPK provides useful information in the development of p38 MAPK inhibitors with therapeutic benefits with reduced side effects. In this review, we summarize and present the list of p38 MAPK inhibitors in in vitro/in vivo studies as well as in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both signaling pathways are key regulators of inflammation and pro-inflammatory responses, which are considered targets for developing anti-inflammatory therapeutic agents [23–26].”
From The potential of GHK as an anti-aging peptide (2020) · cites this paper as [25]
Citations
Cites
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034 · cited 15×
“Loss of p38 MAPK activation in MKK3/MMK6-knockout animals was associated with defects in growth arrest and increased tumorigenic potential [138].”
BackgroundInfluentialKyriakis, J. M., & Avruch, J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.807 · Cited by 3,382 · cited 1×
“p38 MAPK is activated by pro-inflammatory cytokines such as interleukins and TNF-a [11,12].”
BackgroundA protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288 · cited 1×
“The p38 MAPK, originally referred as cytokine-suppressive anti-inflammatory drug binding protein (CSBP), was first discovered in 1994 as 38 kDa protein kinase involved in the regulation of inflammatory cytokine biosynthesis [7].”
BackgroundMAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“Several excellent review articles [1,4-6] describe the properties and potential implications of p38 MAPK in diseases.”
BackgroundCancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720 · cited 1×
“The p38 MAPK pathway has been shown to regulate the expression of the MMP family [42,45,79], which is significantly involved in tumor invasion and metastasis formation in various cell systems [80,81].”
BackgroundA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · cited 2×
“Drugs (2009) 18(12) for p38a and p38b over the majority of kinases, but does inhibit some MAPKs, such as JNK3 [102,103].”
BackgroundRaingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., & Davis, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7420 · Cited by 2,241 · cited 1×
“The p38 MAPK pathway is also activated through stimulation of receptors including GPCR, cytokine receptors, Toll-like receptors, growth factor receptors, and receptors associated with environmental stress such as heat shock, radiation and ultraviolet light [5,13,14], demonstrating that a variety of signaling events tr…”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 2×
“Drugs (2009) 18(12) for p38a and p38b over the majority of kinases, but does inhibit some MAPKs, such as JNK3 [102,103].”
BackgroundThe p38 signal transduction pathway Activation and function
Ono, K., & Han, J. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(99)00071-6 · Cited by 1,571 · cited 3×
“The p38 MAPK cascade is known to be activated by various pro-inflammatory and stressful stimuli and thus plays an essential role in cellular responses including inflammation, cell proliferation, differentiation, apoptosis, and invasion [1-3].”
BackgroundKaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285 · cited 1×
“Several excellent review articles [1,4-6] describe the properties and potential implications of p38 MAPK in diseases.”
BackgroundCytokines and acute neurodegeneration
Allan, S. M., & Rothwell, N. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35094583 · Cited by 1,123
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions
Pearson, G. (2001) · Endocrine Reviews · doi:10.1210/er.22.2.153 · Cited by 1,060
Wang, X., & Ron, D. (1996) · Science · doi:10.1126/science.272.5266.1347 · Cited by 883 · cited 4×
“Our recent study has demonstrated that ATF-2 mediates MMP-2 transcriptional activation induced by p38 MAPK in MCF10A human breast epithelial cells [42]. p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundInfluentialInhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833 · cited 1×
“The ureacontaining p38a inhibitors such as BIRB-796 bind to the site remote from the ATP pocket, and prevent ATP binding [101].”
BackgroundActivation of the transcription factor MEF2C by the MAP kinase p38 in inflammation
Han, J., Jiang, Y., Li, Z., Kravchenko, V. V., & Ulevitch, R. J. (1997) · Nature · doi:10.1038/386296a0 · Cited by 766 · cited 4×
“Our recent study has demonstrated that ATF-2 mediates MMP-2 transcriptional activation induced by p38 MAPK in MCF10A human breast epithelial cells [42]. p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundInfluentialMAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis
Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., & Gaestel, M. (1999) · Nature Cell Biology · doi:10.1038/10061 · Cited by 763
Vermeulen, L. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg139 · Cited by 760 · cited 4×
“Our recent study has demonstrated that ATF-2 mediates MMP-2 transcriptional activation induced by p38 MAPK in MCF10A human breast epithelial cells [42]. p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundInfluentialTGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses
Yu, L. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf366 · Cited by 721
p38-dependent marking of inflammatory genes for increased NF-κB recruitment
Saccani, S., Pantano, S., & Natoli, G. (2002) · Nature Immunology · doi:10.1038/ni748 · Cited by 693
Bagrodia, S., Dérijard, B., Davis, R. J., & Cerione, R. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.47.27995 · Cited by 635 · cited 1×
“Rac and Cdc42 have been identified as potential regulators of the p38 MAPK pathway: co-expression of constitutively active forms of Rac and Cdc42 leads to activation of p38 MAPK, while dominant-negative constructs of Rac and Cdc42 inhibit the ability of IL-1 to increase p38 MAPK activity [26,27].”
BackgroundZhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., & Bokoch, G. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23934 · Cited by 614 · cited 1×
“Rac and Cdc42 have been identified as potential regulators of the p38 MAPK pathway: co-expression of constitutively active forms of Rac and Cdc42 leads to activation of p38 MAPK, while dominant-negative constructs of Rac and Cdc42 inhibit the ability of IL-1 to increase p38 MAPK activity [26,27].”
BackgroundEnslen, H., Raingeaud, J., & Davis, R. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1741 · Cited by 539 · cited 1×
“Selective activation of p38 MAPK isoforms by upstream kinases has been observed [17-20].”
BackgroundSugden, P. H., & Clerk, A. (1998) · Circulation Research · doi:10.1161/01.res.83.4.345 · Cited by 513 · cited 1×
“The p38 MAPK pathway is also activated through stimulation of receptors including GPCR, cytokine receptors, Toll-like receptors, growth factor receptors, and receptors associated with environmental stress such as heat shock, radiation and ultraviolet light [5,13,14], demonstrating that a variety of signaling events tr…”
BackgroundCharacterization of the Structure and Function of a Novel MAP Kinase Kinase (MKK6)
Han, J., Lee, J.-D., Jiang, Y., Li, Z., Feng, L., & Ulevitch, R. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.6.2886 · Cited by 512 · cited 10×
“Loss of p38 MAPK activation in MKK3/MMK6-knockout animals was associated with defects in growth arrest and increased tumorigenic potential [138].”
BackgroundInfluentialBadger, A. M., Bradbeer, J. N., Votta, B., Lee, J. C., Adams, J. L., & Griswold, D. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21307-6 · Cited by 499 · cited 3×
“3 Systemic inflammation p38MAPK inhibitors have been shown to reduce LPS-induced TNF-a production [56].”
BackgroundMechanism of p38 MAP kinase activation in vivo
Brancho, D., Tanaka, N., Jaeschke, A., Ventura, J.-J., Kelkar, N., Tanaka, Y., Kyuuma, M., Takeshita, T., Flavell, R. A., & Davis, R. J. (2003) · Genes & Development · doi:10.1101/gad.1107303 · Cited by 490 · cited 1×
“Loss of p38 MAPK activation in MKK3/MMK6-knockout animals was associated with defects in growth arrest and increased tumorigenic potential [138].”
BackgroundJiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., Di Padova, F., Ulevitch, R. J., & Han, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30122 · Cited by 489
Role of p38 and JNK Mitogen-Activated Protein Kinases in the Activation of Ternary Complex Factors
Whitmarsh, A. J., Yang, S.-H., Su, M. S.-S., Sharrocks, A. D., & Davis, R. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2360 · Cited by 455 · cited 1×
“Several groups have reported that p38 MAPK inhibition induced activation of JNK in many human cell types [135-137].”
BackgroundA Novel Kinase Cascade Mediated by Mitogen-activated Protein Kinase Kinase 6 and MKK3
Moriguchi, T., Kuroyanagi, N., Yamaguchi, K., Gotoh, Y., Irie, K., Kano, T., Shirakabe, K., Muro, Y., Shibuya, H., Matsumoto, K., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13675 · Cited by 447 · cited 1×
“Many studies have documented that MKK6 is the major activator of p38 MAPK [21-24].”
BackgroundShe, Q., Bode, A. M., Ma, W., Chen, N. Y., & Dong, Z. (2001) · PubMed · Cited by 444
The p38 Mitogen-activated Protein Kinase Is Required for NF-κB-dependent Gene Expression
Carter, A. B., Knudtson, K. L., Monick, M. M., & Hunninghake, G. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30858 · Cited by 443 · cited 1×
“p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundSummers, R. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00623-3 · Cited by 437 · cited 2×
“Knocking out IL-23 significantly reduced inflammation of the bowel, in terms of cells and pro-inflammatory cytokine production [61].”
BackgroundCuenda, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.2.295 · Cited by 362 · cited 1×
“Selective activation of p38 MAPK isoforms by upstream kinases has been observed [17-20].”
BackgroundERKs and p38 Kinase Phosphorylate p53 Protein at Serine 15 in Response to UV Radiation
She, Q.-B., Chen, N., & Dong, Z. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001020200 · Cited by 346 · cited 1×
“p38 MAPK binds to p53 to form a complex, leading to phosphorylation of p53, thereby enhancing its functional activities [89].”
BackgroundMcLaughlin, M. M., Kumar, S., McDonnell, P. C., Van Horn, S., Lee, J. C., Livi, G. P., & Young, P. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8488 · Cited by 342 · cited 1×
“A closely related protein kinase, MK3, was also shown to be a substrate of p38a [35].”
BackgroundRequirement of p38 Mitogen-activated Protein Kinase for Neuronal Differentiation in PC12 Cells
Morooka, T., & Nishida, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24285 · Cited by 340 · cited 3×
“Cancer-related diseases In vitro: PC12 cancer cells Block of neuronal outgrowth [74]”
BackgroundNuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2
Ben-Levy, R., Hooper, S., Wilson, R., Paterson, H. F., & Marshall, C. J. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70442-7 · Cited by 338 · cited 2×
“It has been demonstrated that p38 MAPK and MK2 exist as a preformed complex, located within the nucleus [33].”
BackgroundThe kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling
Ananieva, O., Darragh, J., Johansen, C., Carr, J. M., McIlrath, J., Park, J. M., Wingate, A., Monk, C. E., Toth, R., Santos, S. G., et al. (2008) · Nature Immunology · doi:10.1038/ni.1644 · Cited by 326 · cited 2×
“p38a activates mitogen and stress-activated kinase 1 (MSK1) and MSK2, which prevent the production of pro-inflammatory cytokines and thus limit inflammatory responses [142,144].”
BackgroundPRAK, a novel protein kinase regulated by the p38 MAP kinase
New, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3372 · Cited by 319 · cited 1×
“PRAK, a stress-activated protein, can be activated by p38a and p38b [36].”
BackgroundTargeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316 · cited 2×
“The downregulation of p38a in adult mice leads to an immature and hyperproliferative lung epithelium that is highly sensitized to tumorigenesis induced by the K-ras G12V [139,140]. p38a can activate anti-inflammatory cytokines as well as the proinflammatory cytokines [141-143], and its inhibitors may suppress both ant…”
BackgroundChanges in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., Syed, A., Fritsche, H. A., Bruera, E., Booser, D., et al. (2004) · Cytokine · doi:10.1016/j.cyto.2003.10.004 · Cited by 312 · cited 1×
“4 RWJ-67657 (Johnson & Johnson) RWJ-67657 was reported to reduce TNF-a, IL-6 and IL-8 (which have been associated with the development of flu-like symptoms [119]) in a dose-dependent manner [120].”
BackgroundSweeney, G., Somwar, R., Ramlal, T., Volchuk, A., Ueyama, A., & Klip, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10071 · Cited by 310 · cited 1×
“It must be noted that the activation of p38 MAPK is dependent on cell type [15,16].”
Backgroundp38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation
Ventura, J. J., Tenbaum, S., Perdiguero, E., Huth, M., Guerra, C., Barbacid, M., Pasparakis, M., & Nebreda, A. R. (2007) · Nature Genetics · doi:10.1038/ng2037 · Cited by 304
Nick, J. A., Avdi, N. J., Young, S. K., Knall, C., Gerwins, P., Johnson, G. L., & Worthen, G. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119263 · Cited by 300 · cited 1×
“Not only the small G-proteins but the large G-proteins such as GPCR and regulators of G-protein signaling (RGS) proteins are also involved in the p38 MAPK signaling pathway [29,30].”
BackgroundUnderwood, D. C., Osborn, R. R., Bochnowicz, S., Webb, E. F., Rieman, D. J., Lee, J. C., Romanic, A. M., Adams, J. L., Hay, D. W. P., & Griswold, D. E. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.279.5.l895 · Cited by 297 · cited 12×
“Expression of many cytokines, transcription factors, cell surface receptors and enzymes including IL-1, IL-6, IL-8, TNF-a, iNOS, COX2, MMP-1, MMP-2, MMP-9, MMP-13, c-jun, c-fos, junB, and LDL receptor has been demonstrated to be regulated by the p38 MAPK pathway [1,42].”
BackgroundInfluentialRidley, S. H., Sarsfield, S. J., Lee, J. C., Bigg, H. F., Cawston, T. E., Taylor, D. J., DeWitt, D. L., & Saklatvala, J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3165 · Cited by 286 · cited 3×
“The p38 MAPK activation is critical for induction of the expression of invasion-associated MMPs such as MMP-13, MMP-1 and MMP-9 in transformed keratinocytes [87].”
BackgroundHale, K. K., Trollinger, D. B., Rihanek, M., & Manthey, C. L. (1999) · PubMed · Cited by 282
Leptomycin B-sensitive nuclear export of MAPKAP kinase 2is regulated by phosphorylation
Engel, K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3363 · Cited by 265
McDonald, D. R., Bamberger, M. E., Combs, C. K., & Landreth, G. E. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-12-04451.1998 · Cited by 252 · cited 1×
“McDonald and colleagues [64] reported that p38 MAPK was upregulated in the brains of a transgenic mouse model of Alzheimer’s disease.”
BackgroundBrook, M., Tchen, C. R., Santalucia, T., McIlrath, J., Arthur, J. S. C., Saklatvala, J., & Clark, A. R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2408-2418.2006 · Cited by 250 · cited 1×
“p38a can activate anti-inflammatory cytokines as well as the proinflammatory cytokines [141-143], and its inhibitors may suppress both anti-inflammatory and pro-inflammatory effects.”
BackgroundType IV collagenases in invasive tumors
Tryggvason, K., Höyhtyä, M., & Pyke, C. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf01833261 · Cited by 249
Hale, K. K., Trollinger, D., Rihanek, M., & Manthey, C. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.4246 · Cited by 245
Targeting of p38 Mitogen-Activated Protein Kinases to MEF2 Transcription Factors
Yang, S.-H., Galanis, A., & Sharrocks, A. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4028 · Cited by 244 · cited 4×
“Our recent study has demonstrated that ATF-2 mediates MMP-2 transcriptional activation induced by p38 MAPK in MCF10A human breast epithelial cells [42]. p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundInfluentialJohansson, N., Ala-aho, R., Uitto, V.-J., Grénman, R., Fusenig, N. E., López-OtÍn, C., & Kähäri, V.-M. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.2.227 · Cited by 243
Damjanov, N., Kauffman, R. S., & Spencer‐Green, G. T. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24485 · Cited by 242 · cited 2×
“VX-702 RA ACS Reduced serum levels of CRP in patients undergoing PCI Only modest ACR20 response plus the transient suppression of inflammatory biomarkers was observed [131-133]”
BackgroundGeneration and Characterization of p38β (MAPK11) Gene-Targeted Mice
Beardmore, V. A., Hinton, H. J., Eftychi, C., Apostolaki, M., Armaka, M., Darragh, J., McIlrath, J., Carr, J. M., Armit, L. J., Clacher, C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10454-10464.2005 · Cited by 236 · cited 1×
“The p38b(-/-) mice showed normal lipopolysaccharide (LPS)-induced cytokine production, suggesting that p38a MAPK is the major isoform involved in the immune and inflammatory responses [10].”
BackgroundSimon, C., Goepfert, H., & Boyd, D. (1998) · PubMed · Cited by 235
Cohen, S. B., Cheng, T., Chindalore, V., Damjanov, N., Burgos‐Vargas, R., DeLora, P., Zimany, K., Travers, H., & Caulfield, J. P. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24266 · Cited by 231 · cited 2×
“Roche Pamapimod (RO4402257) RA Lower frequencies of ACR20 and DAS28 response compared with methotrexate-taking group ACR20 response was not significant from placebo and the decrease of CRP were lost by week 4 [117,118]”
BackgroundMethodBadger, A. M., Griswold, D. E., Kapadia, R. D., Blake, S. M., Swift, B. A., Hoffman, S. J., Stroup, G. B., Webb, E. F., Rieman, D. J., Gowen, M., et al. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<175::aid-anr22>3.0.co;2-s · Cited by 230 · cited 3×
“SB242235 RA In vivo: Murine model of adjuvant-induced arthritis Inhibition of TNF-a [58]”
Backgroundp38 Pathway Kinases as Anti-inflammatory Drug Targets
Schindler, J. F., Monahan, J. B., & Smith, W. G. (2007) · Journal of Dental Research · doi:10.1177/154405910708600902 · Cited by 227 · cited 8×
“A 28-day randomized, double-blind, placebo-controlled study in individuals with coronary heart disease undergoing percutaneous coronary intervention is also currently underway [5].”
BackgroundMethodInfluentialLee, M. R., & Dominguez, C. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774462914 · Cited by 223
Kim, E.-S., Kim, M.-S., & Moon, A. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.5.1375 · Cited by 219 · cited 3×
“SB203580 Asthma In vivo: in BAL fluid of rat Inhibition of TNF-a and IL-1b production [51,52] RA In vivo: Murine model of collagen-induced arthritis Prevention of RA progression [56] Inflammatory bowel disease In vivo: DSS-induced ulcerative colitis mice model Reduction of mRNA levels of proinflammatory cytokines RICK…”
BackgroundSelf-citationRonkina, N., Kotlyarov, A., Dittrich-Breiholz, O., Kracht, M., Hitti, E., Milarski, K., Askew, R., Marusic, S., Lin, L.-L., Gaestel, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01456-06 · Cited by 216 · cited 1×
“p38a can activate anti-inflammatory cytokines as well as the proinflammatory cytokines [141-143], and its inhibitors may suppress both anti-inflammatory and pro-inflammatory effects.”
BackgroundBarone, F. C., Irving, E. A., Ray, A. M., Lee, J. C., Kassis, S., Kumar, S., Badger, A. M., White, R. F., McVey, M. J., Legos, J. J., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38747-6 · Cited by 214 · cited 3×
“Brain inflammation and stroke In vivo: in rat Reduction of infarct volume [65-67]”
BackgroundXu, L., Chen, S., & Bergan, R. C. (2006) · Oncogene · doi:10.1038/sj.onc.1209337 · Cited by 213 · cited 1×
“It has been demonstrated that prostate cancer cell invasion is mediated through the p38 MAPK pathway; this leads to the phosphorylation of heat shock protein 27, which in turn regulates MMP-2 activation and cell invasion [82].”
BackgroundBadger, A. M., Griswold, D. E., Kapadia, R. D., Blake, S. M., Swift, B. A., Hoffman, S. J., Stroup, G. B., Webb, E. F., Rieman, D. J., Gowen, M., et al. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<1::aid-anr1>3.0.co;2-6 · Cited by 213
Pietersma, A., Tilly, B. C., Gaestel, M., de Jong, N., Lee, J. C., Koster, J. F., & Sluiter, W. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5886 · Cited by 212 · cited 1×
“p38 MAPK participates in GM-CSF, CSF, EPO, and CD40-induced cell proliferation and/or differentiation [46,47].”
BackgroundInhibition of p38 MAP kinase‐and RICK/NF‐κB‐signaling suppresses inflammatory bowel disease
Hollenbach, E., Neumann, M., Vieth, M., Roessner, A., Malfertheiner, P., & Naumann, M. (2004) · The FASEB Journal · doi:10.1096/fj.04-1642fje · Cited by 211
p38 MAPK in Development and Cancer
Bradham, C., & McClay, D. R. (2006) · Cell Cycle · doi:10.4161/cc.5.8.2685 · Cited by 210 · cited 2×
“Similarly, opposed effects of p38MAPK have been observed with respect to cell cycle regulation [91].”
BackgroundTargeting protein kinases for the development of anti-inflammatory drugs
Cohen, P. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.015 · Cited by 207 · cited 2×
“p38a activates mitogen and stress-activated kinase 1 (MSK1) and MSK2, which prevent the production of pro-inflammatory cytokines and thus limit inflammatory responses [142,144].”
BackgroundWang, Y., Singh, R., Lefkowitch, J. H., Rigoli, R. M., & Czaja, M. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512953200 · Cited by 207
CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family
Maroney, A. C., Finn, J. P., Connors, T. J., Durkin, J. T., Angeles, T., Gessner, G., Xu, Z., Meyer, S. L., Savage, M. J., Greene, L. A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011601200 · Cited by 204 · cited 2×
“When the APP751 mice were treated with a p38 MAPK inhibitor, SD282, it protected the brain from ischemic injury and abolished the difference in ischemic vulnerability [69].”
Backgroundp38 MAPK Is Required for CD40-Induced Gene Expression and Proliferation in B Lymphocytes
Craxton, A., Shu, G., Graves, J. D., Saklatvala, J., Krebs, E. G., & Clark, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3225 · Cited by 197 · cited 1×
“p38 MAPK participates in GM-CSF, CSF, EPO, and CD40-induced cell proliferation and/or differentiation [46,47].”
BackgroundStein, B., Brady, H., Yang, M. X., Young, D. B., & Barbosa, M. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11427 · Cited by 190 · cited 1×
“Many studies have documented that MKK6 is the major activator of p38 MAPK [21-24].”
BackgroundKim, M., Lee, E.-J., Kim, H.-R. C., & Moon, A. (2003) · PubMed · Cited by 190
Self-citationSchreiber, S., Feagan, B., D’Haens, G., Colombel, J., Geboes, K., Yurcov, M., Isakov, V., Golovenko, O., Bernstein, C. N., Ludwig, D., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.11.013 · Cited by 186 · cited 2×
“BIRB-796 was tested in an 8-week study of 284 persons with moderate to severe Crohn’s disease, but failed to show any clinical benefit [116].”
BackgroundMethodH-Ras-specific Activation of Rac-MKK3/6-p38 Pathway
Shin, I., Kim, S., Song, H., Kim, H.-R. C., & Moon, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411625200 · Cited by 185 · cited 2×
“The p38 MAPK pathway has been shown to regulate the expression of the MMP family [42,45,79], which is significantly involved in tumor invasion and metastasis formation in various cell systems [80,81].”
BackgroundSelf-citationElenitoba-Johnson, K. S. J., Jenson, S. D., Abbott, R. T., Palais, R. A., Bohling, S. D., Lin, Z., Tripp, S., Shami, P. J., Wang, L. Y., Coupland, R. W., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1137463100 · Cited by 185 · cited 1×
“p38 MAPK has been shown to induce apoptosis in some cells, but plays an anti-apoptotic role in a number of other cell types [96,97].”
BackgroundStructural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
Fitzgerald, C. E., Patel, S. B., Becker, J. W., Cameron, P. M., Zaller, D., Pikounis, V. B., O'Keefe, S. J., & Scapin, G. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb949 · Cited by 182 · cited 1×
“7 VX-745/VX-702 (Vertex) VX-745 was reported to inhibit production of LPS-induced TNF-a in whole blood [128].”
BackgroundJackson, J. R., Bolognese, B., Hillegass, L., Kassis, S., Adams, J., Griswold, D. E., & Winkler, J. D. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37283-0 · Cited by 174 · cited 3×
“SB220025 RA In vivo: Murine model of collagen-induced arthritis Prevention of RA progression [57]”
BackgroundYao, J., Xiong, S., Klos, K., Nguyen, N., Grijalva, R., Li, P., & Yu, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204944 · Cited by 168 · cited 1×
“It was also suggested that p38 MAPK might be critical in heregulin-b1-mediated MMP-9 induction in breast cancer cells [88].”
BackgroundKotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H., & Gaestel, M. (1999) · Cited by 167
Purification and Identification of a Major Activator for p38 from Osmotically Shocked Cells
Moriguchi, T., Toyoshima, F., Gotoh, Y., Iwamatsu, A., Irie, K., Mori, E., Kuroyanagi, N., Hagiwara, M., Matsumoto, K., & Nishida, E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26981 · Cited by 165
p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez, C., Powers, D. A., & Tamayo, N. A. (2005) · PubMed · Cited by 163
Koistinaho, M., Kettunen, M. I., Goldsteins, G., Keinänen, R., Salminen, A., Ort, M., Bures, J., Liu, D., Kauppinen, R. A., Higgins, L. S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032670899 · Cited by 159
RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase
Wadsworth, S. A., Cavender, D. E., Beers, S. A., Lalan, P., Schafer, P. H., Malloy, E. A., Wu, W., Fahmy, B., Olini, G. C., Davis, J. E., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35155-9 · Cited by 157 · cited 3×
“RWJ67657 Systemic inflammation In vivo: LPS-injected mice and rats Reduction of TNF-a release [60]”
BackgroundMethodResultInvolvement of the p38 mitogen‐activated protein kinase cascade in hepatocellular carcinoma
Iyoda, K., Sasaki, Y., Horimoto, M., Toyama, T., Yakushijin, T., Sakakibara, M., Takehara, T., Fujimoto, J., Hori, M., Wands, J. R., et al. (2003) · Cancer · doi:10.1002/cncr.11425 · Cited by 148 · cited 1×
“p38 MAPK activity has been shown to induce apoptosis in hepatocellular carcinoma cell lines [92].”
BackgroundCorrelation Between Dry Eye and Rheumatoid Arthritis Activity
Fujita, M., Igarashi, T., Kurai, T., Sakane, M., Yoshino, S., & Takahashi, H. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.05.025 · Cited by 147 · cited 1×
“It causes inflammation in the lining of the joints and/or other internal organs [53].”
BackgroundMAPKAP Kinase 2-Deficient Mice Are Resistant to Collagen-Induced Arthritis
Hegen, M., Gaestel, M., Nickerson-Nutter, C. L., Lin, L.-L., & Telliez, J.-B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1913 · Cited by 146 · cited 11×
“Expression of many cytokines, transcription factors, cell surface receptors and enzymes including IL-1, IL-6, IL-8, TNF-a, iNOS, COX2, MMP-1, MMP-2, MMP-9, MMP-13, c-jun, c-fos, junB, and LDL receptor has been demonstrated to be regulated by the p38 MAPK pathway [1,42].”
BackgroundInfluentialSignal transduction in rheumatoid arthritis
Sweeney, S. E., & Firestein, G. S. (2004) · Current Opinion in Rheumatology · doi:10.1097/00002281-200405000-00011 · Cited by 144 · cited 1×
“The p38 MAPK signaling pathway is associated with RA, and preclinical models showed the therapeutic potential of small-molecule inhibitors [54,55].”
BackgroundCampbell, J., Ciesielski, C. J., Hunt, A. E., Horwood, N. J., Beech, J. T., Hayes, L. A., Denys, A., Feldmann, M., Brennan, F. M., & Foxwell, B. M. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6928 · Cited by 135 · cited 1×
“p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundIncreased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells
Guo, X., Ma, N., Wang, J., Song, J., Bu, X., Cheng, Y., Sun, K., Xiong, H., Jiang, G., Zhang, B., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-375 · Cited by 130 · cited 3×
“SB202190 Cancer In vitro: Human gastric cancer cells Reduction of AP-1 activity Increase of the sensitivity of chemotherapy [77]”
BackgroundInfluentialJunttila, M. R., Ala-aho, R., Jokilehto, T., Peltonen, J., Kallajoki, M., Grenman, R., Jaakkola, P., Westermarck, J., & Kähäri, V.-M. (2007) · Oncogene · doi:10.1038/sj.onc.1210332 · Cited by 127
Kim, E., Sohn, Y., & Moon, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.016 · Cited by 126
Self-citationMuniyappa, H., & Das, K. C. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.12.003 · Cited by 122 · cited 3×
“Several groups have reported that p38 MAPK inhibition induced activation of JNK in many human cell types [135-137].”
BackgroundInfluentialSimon, C., Simon, M., Vucelic, G., Hicks, J. M., Plinkert, P. K., Koitschev, A., & Zenner, H. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5374 · Cited by 120 · cited 2×
“The p38 MAPK pathway stimulated MMP-9 expression/secretion and in vitro invasion of human squamous carcinoma cell lines [71].”
BackgroundHu, M. C. ‐., Wang, Y., Mikhail, A. A., Qiu, W. R., & Tan, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7095 · Cited by 117 · cited 2×
“Selective activation of p38 MAPK isoforms by upstream kinases has been observed [17-20].”
BackgroundSong, H. B., Ki, S. H., Kim, S. G., & Moon, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1461 · Cited by 111 · cited 12×
“The p38 MAPK pathway activates ATF-2, which then results in transcriptional activation of MMP-2 through binding to the functional AP-1 site [42].”
BackgroundInfluentialSelf-citationInhibition of p38 Mitogen-activated Protein Kinase by Insulin in Cultured Fetal Neurons
Heidenreich, K. A., & Kummer, J. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.17.9891 · Cited by 107 · cited 1×
“It must be noted that the activation of p38 MAPK is dependent on cell type [15,16].”
BackgroundFijen, J. W., Zijlstra, J. G., De Boer, P., Spanjersberg, R., Cohen Tervaert, J. W., Van Der Werf, T. S., Ligtenberg, J. J. M., & Tulleken, J. E. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2001.01485.x · Cited by 101 · cited 1×
“4 RWJ-67657 (Johnson & Johnson) RWJ-67657 was reported to reduce TNF-a, IL-6 and IL-8 (which have been associated with the development of flu-like symptoms [119]) in a dose-dependent manner [120].”
BackgroundSB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
Legos, J. J., Erhardt, J. A., White, R. F., Lenhard, S. C., Chandra, S., Parsons, A. A., Tuma, R. F., & Barone, F. C. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03228-5 · Cited by 100 · cited 3×
“Brain inflammation and stroke In vivo: in rat Reduction of infarct volume [65-67]”
BackgroundHeinrichsdorff, J., Luedde, T., Perdiguero, E., Nebreda, A. R., & Pasparakis, M. (2008) · EMBO reports · doi:10.1038/embor.2008.149 · Cited by 99 · cited 3×
“Several groups have reported that p38 MAPK inhibition induced activation of JNK in many human cell types [135-137].”
BackgroundInhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.
Pargellis, C., & Regan, J. R. (2003) · PubMed · Cited by 99
Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction
Mbalaviele, G., Anderson, G. D., Jones, A., Ciechi, P. D., Settle, S., Mnich, S., Thiede, M. A., Abu‐Amer, Y., Portanova, J. P., & Monahan, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100362 · Cited by 97 · cited 1×
“Additionally, p38 MAPK regulates osteoclast differentiation and bone resorption through modulation of RANKL expression [49].”
BackgroundRole of p38 MAP kinase in LPS‐induced airway inflammation in the rat
Haddad, E., Birrell, M., McCluskie, K., Ling, A., Webber, S. E., Foster, M. L., & Belvisi, M. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704022 · Cited by 88 · cited 3×
“SB203580 has been shown to inhibit the production of TNF-a and IL-1b in the bronchoalveolar lavage (BAL) fluid of rats [51,52].”
BackgroundJanus Kinase 2-dependent Activation of p38 Mitogen-activated Protein Kinase by Growth Hormone
Zhu, T., & Lobie, P. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.3.2103 · Cited by 85 · cited 4×
“Our recent study has demonstrated that ATF-2 mediates MMP-2 transcriptional activation induced by p38 MAPK in MCF10A human breast epithelial cells [42]. p38 MAPK can modulate transcriptional upregulation of TNF-a expression and regulate NF-kB-dependent gene expression in LPS-stimulated macrophages [43,44].”
BackgroundInfluentialSong, H. B., & Moon, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.019 · Cited by 81 · cited 2×
“In vitro: Human glioma cells Inhibition of GDNF-induced migration [110]”
BackgroundSelf-citationNavas, T. A., Nguyen, A. N., Hideshima, T., Reddy, M. M., Ma, J. Y., Haghnazari, E., Henson, M., Stebbins, E. G., Kerr, I., O’Young, G., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404200 · Cited by 79
Branger, J., van den Blink, B., Weijer, S., Gupta, A., van Deventer, S. J. H., Hack, C. E., Peppelenbosch, M. P., & van der Poll, T. (2003) · Blood · doi:10.1182/blood-2002-11-3338 · Cited by 79 · cited 1×
“A 600-mg dose of BIRB-796BS significantly inhibited LPS-induced coagulation, fibrinolysis and endothelial cell activation in a dose-dependent manner during human endotoxemia [115].”
BackgroundHill, R. J., Dabbagh, K., Phippard, D., Li, C. L., Suttmann, R. T., Welch, M., Papp, E., Song, K. W., Chang, K.-C., Leaffer, D., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139006 · Cited by 78 · cited 2×
“Kd values were determined for all kinases that demonstrated > 85% inhibition [106].”
BackgroundDavidson, B., Givant-Horwitz, V., Lazarovici, P., Risberg, B. Å., Nesland, J. M., Tropé, C. G., SCHAEFER, E. M., & Reich, R. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1027347932543 · Cited by 76 · cited 2×
“In metastatic serous ovarian carcinoma, MMP-2 activity also correlated with p38 MAPK activity [73].”
BackgroundChang, H.-L., Wu, Y., Su, J., Yeh, Y., & Yuan, S. F. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135442 · Cited by 71 · cited 1×
“An in vivo xenograft study showed that induction of apoptosis was associated with activation of p38 MAPK and JNK1/2 in protoapigenonetreated prostate tumor tissues [94].”
BackgroundAlten, R., Zerbini, C. A. F., Jeka, S., Irazoque, F., Khatib, F., Emery, P., Bertasso, A., Rabbia, M. A., & CAULFIELD, J. P. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104802 · Cited by 68 · cited 2×
“Roche Pamapimod (RO4402257) RA Lower frequencies of ACR20 and DAS28 response compared with methotrexate-taking group ACR20 response was not significant from placebo and the decrease of CRP were lost by week 4 [117,118]”
BackgroundKim, E., Kim, M.-S., & Moon, A. (2004) · Cytokine · doi:10.1016/j.cyto.2004.10.001 · Cited by 65
Self-citationLantos, I., Bender, P. E., Razgaitis, K. A., Sutton, B. M., DiMartino, M. J., Griswold, D. E., & Walz, D. T. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00367a014 · Cited by 65 · cited 1×
“SB203580 is reported to be the first selective inhibitor of p38a and p38b isoforms [99], but is not effective for p38g and p38d [100].”
BackgroundInhibitors of p38 Mitogen-Activated Protein Kinase: Potential as Anti-inflammatory Agents in Asthma?
Newton, R., & Holden, N. S. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00004 · Cited by 64
Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat
Escott, K. J., Belvisi, M. G., Birrell, M. A., Webber, S., Foster, M., & Sargent, C. A. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703605 · Cited by 62 · cited 3×
“SB203580 has been shown to inhibit the production of TNF-a and IL-1b in the bronchoalveolar lavage (BAL) fluid of rats [51,52].”
BackgroundPerregaux, D. G., Dean, D., Cronan, M., Connelly, P., & Gabel, C. A. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10491-4 · Cited by 61 · cited 1×
“p38 MAPK is activated by pro-inflammatory cytokines such as interleukins and TNF-a [11,12].”
BackgroundYasui, H., Hideshima, T., Ikeda, H., Jin, J., Ocio, E. M., Kiziltepe, T., Okawa, Y., Vallet, S., Podar, K., Ishitsuka, K., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06443.x · Cited by 60 · cited 3×
“BIRB-796 Cancer In vitro: Paracrine tumor cell Inhibition of IL-6 secretion and proliferation [78]”
BackgroundCroons, V., Martinet, W., Herman, A. G., Timmermans, J., & Meyer, G. R. Y. D. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149948 · Cited by 59 · cited 2×
“p38 MAPK plays a major role in anisomycin-reduced macrophage content of rabbit atherosclerotic plaques through apoptosis; a p38 MAPK inhibitor, SB202190, prevented macrophage cell death [95].”
BackgroundNovel signal transduction modulators for the treatment of airway diseases
Barnes, P. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.001 · Cited by 56 · cited 1×
“1 Asthma The p38 MAPK signaling pathway is involved in the expression of inflammatory cytokines and environmental stress, and thus may contribute to asthma and autoimmune disease [50].”
BackgroundZhou, H., Pon, Y. L., & Wong, A. S. T. (2007) · Endocrinology · doi:10.1210/en.2007-0361 · Cited by 53 · cited 9×
“Expression of many cytokines, transcription factors, cell surface receptors and enzymes including IL-1, IL-6, IL-8, TNF-a, iNOS, COX2, MMP-1, MMP-2, MMP-9, MMP-13, c-jun, c-fos, junB, and LDL receptor has been demonstrated to be regulated by the p38 MAPK pathway [1,42].”
BackgroundInfluentialp38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
Behr, T. M., Berova, M., Doe, C. P. A., Ju, H., Angermann, C. E., Boehm, J. C., & Willette, R. N. (2003) · PubMed · Cited by 53
Zhang, Y., Neo, S. Y., Han, J., Yaw, L. P., & Lin, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2851 · Cited by 52
Denkert, C., Siegert, A., Leclere, A., Turzynski, A., & Hauptmann, S. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1013857325012 · Cited by 50 · cited 1×
“The activation of MMP-2 and the invasiveness have been shown to be mediated through p38 MAPK, but not ERK, signaling in human melanoma cells [83].”
Backgroundp38 MAP kinase inhibitors: A future therapy for inflammatory diseases
Mayer, R. J., & Callahan, J. F. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.03.003 · Cited by 48 · cited 1×
“Some of the p38 MAPK inhibitors may eventually be found useful as anti-inflammatory drugs in situations where local application might be possible and/or where the treatment period is relatively short [144,145].”
BackgroundR-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models
Wada, Y., Nakajima-Yamada, T., Yamada, K., Tsuchida, J., Yasumoto, T., Shimozato, T., Aoki, K., Kimura, T., & Ushiyama, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.11.013 · Cited by 42 · cited 2×
“R-130823 RA In vivo: Murine model of adjuvant-induced arthritis Reduction of hind paw swelling [59]”
BackgroundYamauchi, J., Tsujimoto, G., Kaziro, Y., & Itoh, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011752200 · Cited by 40 · cited 4×
“Genes that are regulated by p38 MAPK have been revealed by using dominant negative mutants of the upstream activators of p38 MAPK, MKK3 and MKK6, as well as pharmacological inhibitors of p38 MAPK.”
BackgroundInfluentialKarahashi, H., Nagata, K., Ishii, K., & Amano, F. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00045-4 · Cited by 35 · cited 1×
“p38 MAPK has been shown to induce apoptosis in some cells, but plays an anti-apoptotic role in a number of other cell types [96,97].”
BackgroundRust, W. L., Kingsley, K., Petnicki, T., Padmanabhan, S., Carper, S. W., & Plopper, G. E. (1999) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.1999.0130 · Cited by 32 · cited 2×
“Phosphorylation of heat shock protein 27 by p38 MAPK has been shown to induce the migration of MDA-MB-231 breast cancer cells on a laminin-5-coated dish [70].”
BackgroundGruenbaum, L. M., Schwartz, R., Woska, J. R., DeLeon, R. P., Peet, G. W., Warren, T. C., Capolino, A. J., Mara, L., Morelock, M. M., Shrutkowski, A., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.032 · Cited by 32 · cited 1×
“It exerted comparable inhibition of TNF-a production [114].”
BackgroundIntracellular signaling pathways as a target for the treatment of rheumatoid arthritis
Kumar, S., Blake, S. M., & Emery, J. G. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00054-6 · Cited by 32 · cited 1×
“The p38 MAPK signaling pathway is associated with RA, and preclinical models showed the therapeutic potential of small-molecule inhibitors [54,55].”
BackgroundModern analytical technologies for the detection of drug abuse and doping
Huestis, M. A., & Smith, M. L. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.03.004 · Cited by 27
p38MAPK inhibitor SB203580 sensitizes human SNU-C4 colon cancer cells to exisulind-induced apoptosis
Lim, S., Lee, Y.-J., & Lee, E. (2006) · Oncology Reports · doi:10.3892/or.16.5.1131 · Cited by 23 · cited 3×
“SB203580 significantly sensitizes growth inhibition and apoptosis induced by exisulind in colon cancer cells [76].”
BackgroundCorreze, C., Blondeau, J., & Pomérance, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01942 · Cited by 21 · cited 1×
“Inhibition of p38 MAPK decreased the G1-S phase progression in FRTL-5 thyroid cells [93].”
BackgroundSCIO-469, a novel P38A MAPK Inhibitor, provides efficacy in acute post-surgical dental pain
Tong, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.11.011 · Cited by 16 · cited 2×
“7 h in the low and high doses, respectively [126].”
BackgroundHan, Y., Zeng, X., Wang, R., Zhao, Y., Li, B., & Song, M. S. (2007) · PubMed · Cited by 15
Nemoto, T., Kubota, S., Ishida, H., Murata, N., & Hashimoto, D. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i20.3065 · Cited by 14 · cited 2×
“Increased levels of phosphorylated ERKs and p38 MAPK were detected in colon cancer [72].”
BackgroundBraddock, M. (2003) · PubMed · Cited by 1
66th American College of Rheumatology Annual Scientific Meeting
&NA; (2002) · JCR Journal of Clinical Rheumatology · doi:10.1097/00124743-200208000-00006 · Cited by 1
(2001) · doi:10.1002/1098-1128(200103)21:2<129::aid-med1003>3.0.co;2-h
Research works printed but not linked: 15
- Kim MS, 2003, Cancer Res, 63, 5454
- 10.1111/j.1572-0241.2003.07660.x · doi:10.1111/j.1572-0241.2003.07660.x · Paper page
- Lim SJ, 2006, Oncol Rep, 16, 1131
- Han YC, 2007, Ai Zheng, 26, 48
- Simon C, 1998, Cancer Res, 58, 1135
- She QB, 2001, Cancer Res, 61, 1604
- Karahashi H, 2000, Biochem Biophys Acta, 1502, 207
- Kim ES, 2004, Int J Oncol, 25, 1375
- Dominguez C, 2005, Curr Opin Drug Discov Devel, 8, 421
- Mongin-Bulewski C, 2002, Drug Discovery Technology 2002 (Part V) - Overnight Report
- Alten RE, 2009, Ann Rheum Dis
- Behr TM, 2003, Curr Opin Investig Drugs, 4, 1059
- Braddock M, 2003, Inflammation in drug discovery and development SRI's seventh international meeting
- Pargellis C, 2003, Curr Opin Investig Drugs, 4, 566
- Fitzgerald CE, 2003, MAP kinase quinazoline and pyridol-pyrimidine inhibitor specificity Nat Struct Biol, 10, 764
Cited by
Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV
Stukalov, A., Girault, V., Grass, V., Karayel, O., Bergant, V., Urban, C., Haas, D. A., Huang, Y., Oubraham, L., Wang, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03493-4 · Cited by 685
Reactive Oxygen Species in the Activation of MAP Kinases
Son, Y., Kim, S., Chung, H.-T., & Pae, H.-O. (2013) · Methods in Enzymology · doi:10.1016/b978-0-12-405881-1.00002-1 · Cited by 464
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Ma, L., Wu, F., Shao, Q., Chen, G., Xu, L., & Lu, F. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s319260 · Cited by 273
“In fact, many MAPK inhibitors have been evaluated preclinically in a wide range of disease models with a considerable efficacy.(45) Our results were consistent with many previous works.”
Resultde Lima, R. M. T., dos Reis, A. C., de Menezes, A. P. M., Santos, J. V. D. O., Filho, J. W. G. D. O., Ferreira, J. R. D. O., de Alencar, M. V. O. B., da Mata, A. M. O. F., Khan, I. N., Islam, A., et al. (2018) · Phytotherapy Research · doi:10.1002/ptr.6134 · Cited by 256
Metadata
- Authors
- Yong, H.-Y., Koh, M.-S., & Moon, A.
- Affiliations
- Duksung Women's University (KR)
- ORCID
- Moon, Aree
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-10-23
- Volume
- 18
- Issue
- 12
- Pages
- 1893-1905
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2049204919
- Semantic Scholar
- bc7dcb42a3c3bc9e5014f4072d16d27a6600bb7a
- Cited by
- 422
- References
- 141
- Citations by year
- 2026: 20 · 2025: 50 · 2024: 77 · 2023: 46 · 2022: 52 · 2021: 27 · 2020: 22 · 2019: 13 · 2018: 10 · 2017: 10 · 2016: 11 · 2015: 17 · 2014: 14 · 2013: 21 · 2012: 15
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Science and Engineering Foundation
- Johnson and Johnson
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- p38 MAPK, MAPK inhibitors, inflammatory diseases, cancer, MAPK signaling, signal transduction, gene expression regulation, apoptosis, cell proliferation, clinical trials, drug development
- MeSH terms
- Clinical Trials as Topic, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Inflammation, Neoplasms, Signal Transduction, Drugs, Investigational, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.